The mission of the ACTG Network is to reduce the burden of disease due to HIV, tuberculosis, and viral hepatitis.
CHAVI, which was established by NIAID as part of the Global HIV/AIDS Vaccine Enterprise, is designed to answer basic science questions relevant to HIV vaccines and to conduct early phase HIV vaccine clinical trials at clinical sites around the world.
Community Partners (CP) is a group established to promote effective representation of and timely communication among the many communities, in the United States and internationally, that work with and participate in the National Institutes of Health (NIH)-funded HIV/AIDS Clinical Trials Networks.
CONRAD is focused on facilitating the rapid development of safe, acceptable, affordable products and methods that provide contraception and/or prevent the sexual transmission of HIV/AIDS and other infections.
GHAVE is a consortium of organizations committed to the development of a preventive HIV vaccine by implementing shared scientific plans, mobilizing resources, and improving international collaborations.
The HIV Prevention Trials Network develops and tests the safety and efficacy of primarily non-vaccine interventions designed to prevent the transmission of HIV.
The HVTN mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.
The NIAID HIV/AIDS Clinical Trials Networks have been designed to address NIAID’s five HIV/AIDS scientific priorities.
IAVI was founded in 1996 to speed discovery of an HIV vaccine, partners with private companies, academic institutions, and government agencies, including the National Institutes of Health (NIH).
The IeDEA network is an international research consortium established in 2005 by NIAID to provide a rich resource for globally diverse HIV/AIDS data.
The IMPAACT network aims to significantly decrease incident HIV and HIV-associated infections and to decrease mortality and morbidity due to HIV and HIV-associated infections and co-morbidities among infants, children, adolescents and pregnant/postpartum women.
The INSIGHT network conducts HIV treatment trials to define optimal strategies for the management of HIV and other infectious diseases through a global clinical research network.
IPM is a non-profit product development partnership established in 2002 to accelerate the development and availability of a safe and effective microbicide to prevent HIV infection among women in developing countries.
The MTN is a NIAID-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV.
The MACS is an ongoing prospective study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men living in Baltimore, Chicago, Pittsburgh and Los Angeles.
The Office of HIV/AIDS Network Coordination (HANC) works with NIAID and the HIV/AIDS Clinical Trials Networks to facilitate collaboration and coordination on priority areas of research and operations, increase communication, and streamline processes to improve research efficiency.
Office of the U.S. Global AIDS Coordinator, part of the U.S. Department of State, leads the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). PEPFAR aims to combat global HIV/AIDS.
The Population Council conducts research to address critical health and development issues, allowing couples to plan their families and chart their futures. They help people avoid HIV infection and access life-saving HIV services and empower girls to protect themselves and have a say in their own lives.
Pox Protein Public-Private Partnership (P5)
The P5 was established to advance and ultimately license HIV pox-protein vaccine candidates that have the potential to achieve a broad public health impact. The collaborative team includes NIAID, the Bill & Melinda Gates Foundation, the NIAID-funded HVTN, the U.S. Military HIV Research Program, Sanofi Pasteur, and Novartis Vaccines.
NIH will refine its science-driven HIV research enterprise to deliver the innovative, efficient results we need to turn the corner on the HIV/AIDS pandemic.
- 1 of 2
- next ›